Profil
Saurabh Sewak currently works at Foghorn Therapeutics, Inc., as Vice President-Corporate Development from 2022.
Dr. Sewak also formerly worked at Ipsen Pharmaceuticals, Inc., as Chief of Staff & Head-Strategy from 2018 to 2020.
Dr. Sewak received his doctorate degree from the University of Mississippi.
Postes actifs de Saurabh Sewak
| Sociétés | Poste | Début |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Corporate Officer/Principal | 01/01/2022 |
Anciens postes connus de Saurabh Sewak
| Sociétés | Poste | Fin |
|---|---|---|
Ipsen Pharmaceuticals, Inc.
Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Responsable des Ressources Humaines | 01/01/2020 |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit organization dedicated to funding research, education and support services for all blood cancers | Directeur/Membre du Conseil | - |
Formation de Saurabh Sewak
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
University of Mississippi
University of Mississippi Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit organization dedicated to funding research, education and support services for all blood cancers | Commercial Services |
Ipsen Pharmaceuticals, Inc.
Ipsen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
Foghorn Therapeutics, Inc.
Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
















